Fourth-generation CAR-Ts targeting Nectin-4 and FAP in the tumor stroma and releasing IL-7 and CCL19 or IL-12 upon CAR-target interaction are known in Phase I clinical trials for the treatment of solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder cancer, and pancreatic cancer (NCT03932565) (Table 1). Here, FAP is linked to pancreatic neoplasm.